NEAR’s plan to reduce annual issuance to 1.6% would leave holders with less dilution, while cutting the rewards that pay stakers, validators and the protocol treasury. The two-year schedule gives operators time to adjust, but the proposal’s own financial model…FeatureRead More
You might also be interested in reading InMed Pharmaceuticals GAAP EPS of -$3.64, revenue of $1.11M.
